STOCKHOLM — Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm:CALT), a specialty pharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO) for its product TARPEYO. Issued on January 24, 2024, and effective as of today, the patent, numbered 11896719, extends the company’s intellectual property protection for TARPEYO until 2043.
The patent specifically pertains to a method of treating IgA nephropathy using TARPEYO® (budesonide) delayed release capsules, previously developed under the name NEFECON®. With the patent’s issuance, Calliditas has initiated the process for listing the patent in the Orange Book, an important step for maintaining market exclusivity in the United States.
Calliditas CEO Renée Aguiar-Lucander expressed satisfaction with the additional protection the patent offers, stating that it provides a «longer runway until patent expiration» for TARPEYO. Further, the CEO indicated that the company is looking forward to undertaking similar patent application processes in other regions, including Europe and China.
The patent is the second one granted in the United States for TARPEYO, reinforcing Calliditas’ position in the market for treatments of IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease.
This strategic move is part of Calliditas’ broader plan to secure and extend its product’s market exclusivity on a global scale. The company’s intention to file corresponding patent applications in additional territories is indicative of its proactive approach to safeguarding its intellectual property rights internationally.
The information in this article is based on a press release statement.